Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2513652 | Biochemical Pharmacology | 2010 | 11 Pages |
Abstract
In this work, we aimed to build a 3D-model of NIK and to study the binding of pyrazolo[4,3-c]isoquinolines with a view to highlight the structural elements responsible for their inhibitory potency. However, in the course of this work, we unexpectedly found that the pyrazolo[4,3-c]isoquinolines initially reported as NIK inhibitors were neither inhibitors of this enzyme nor of the alternative NF-κB pathway, but were in fact inhibitors of another kinase, the TGF-β activated kinase 1 (TAK1) which is involved in the classical NF-κB pathway.
Graphical abstractDocking of a new inhibitor of TAK1 (IC50 = 0.56 μM) and identification of potential interactions with the hinge region:Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Jérémie Mortier, Raphaël Frederick, Corinne Ganeff, Caroline Remouchamps, Patrice Talaga, Lionel Pochet, Johan Wouters, Jacques Piette, Emmanuel Dejardin, Bernard Masereel,